Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open label long term extension studies
Full text
Figure
Related documents
Combination therapy of cyclosporin with methotrexate and gold in rheumatoid arthritis (2 pilot studies).. Tugwell P, Pincus T, Yocum DE, et al Combination therapy with cyclosporine
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase
Efficacy and safety of abatacept in Korean patients with active rheumatoid arthritis and in- adequate response to methotrexate: A phase III, multi- centre,
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in
To compare the efficacy and safety of ABT-494, a novel selective JAK-1 inhibitor, with placebo in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate
Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with
RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage 1) evaluated the efficacy and safety of two doses of certolizumab with methotrexate, or placebo with metho- trexate